Sign in
AGIO Stock Price, Chart, Stats & News
Agios Pharmaceuticals, Inc.
Save
2.03B
Market cap
–
Current P/E
2.47x
Forward P/E
AGIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 88.26% |
Operating margin | -873.87% |
Pretax margin | -765.89% |
Net margin | -764.01% |
Effective tax rate | 0.25% |
ROA | -31.82% |
ROE | -31.07% |
D/E | 0.03x |
Interest coverage ratio | – |
AGIO valuation
P/E | – |
P/S | 31.92x |
P/B | 1.44x |
P/CF | -4.60x |
P/FCF | -4.57x |
P/OCF | -4.60x |
PEG | 1.81x |
EV multiple | -4.04x |
About
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases.
Similar securities
Based on sector and market capitalization
Report issue